Skip to main content

Treatments of Non-Alcoholic Steatohepatitis (NASH)

Ref-Nr: TA-P-1305


Kurzfassung

Non-alcoholic fatty liver disease (NAFLD), comprising several liver diseases including NAFL and NASH, which is the most frequent liver disease world-wide, is a clinical manifestation of overweight and metabolic syndrome. The prevalence of NAFL is increasing globally. We have identified compounds that are effective for treating non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC).


Hintergrund

Changes in lifestyle over the last few decades such as high caloric intake (e.g. through high-fat, high-fructose and high-glucose diets) combined with a sedentary lifestyle have increased the incidence of overweight and metabolic syndrome, which is characterized by abdominal obesity, insulin resistance, hypertonia and dyslipidemia. The latest WHO cancer report predicts a doubling in cancer incidence within the next two decades, the great majority of which will be attributable to modifiable risk factors such as high caloric intake, smoking and a sedentary lifestyle. The liver, which is the most important metabolic organ in the body, is greatly affected by a chronic state of hypercaloric uptake, overweight, sedentary lifestyle and the resulting pathology (metabolic syndrome). Non-alcoholic fatty liver disease (NAFLD), comprising several liver diseases including NAFL and NASH, which is the most frequent liver disease world-wide, is a clinical manifestation of overweight and metabolic syndrome. The prevalence of NAFL is increasing globally. Currently, 90 million Americans and 40 million Europeans suffer from NAFLD. A significant number of NAFL patients develop non-alcoholic steatohepatitis (NASH), fibrosis and, subsequently, hepatocellular carcinoma (HCC). 


Lösung

Compounds were identified that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with non-alcoholic fatty liver disease (NAFLD). These compounds are effective for treating non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC). Also provided are methods for screening for new NASH therapeutics. 


Vorteile

Treatment of non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC).


Anwendungsbereiche

Pharmaceutical composition


Deutsches Krebsforschungszentrum DKFZ

Dr. Dirk Kuck
06221-42-2945
d.kuck@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Präklinik


Stichworte

Therapeutics, NASH, NAFLD, HCC, treatment

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr